| A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults V Tricou, NN Minh, TP Van, SJ Lee, J Farrar, B Wills, HT Tran, ... PLoS neglected tropical diseases 4 (8), e785, 2010 | 351 | 2010 |
| Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses V Ty Hang, N Minh Nguyet, D The Trung, V Tricou, S Yoksan, ... PLoS neglected tropical diseases 3 (1), e360, 2009 | 311 | 2009 |
| Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue V Tricou, NN Minh, J Farrar, HT Tran, CP Simmons PLoS neglected tropical diseases 5 (9), e1309, 2011 | 233 | 2011 |
| Comparison of two dengue NS1 rapid tests for sensitivity, specificity and relationship to viraemia and antibody responses V Tricou, HTT Vu, NVN Quynh, CVV Nguyen, HT Tran, J Farrar, B Wills, ... BMC infectious diseases 10, 1-8, 2010 | 223 | 2010 |
| Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial S Biswal, C Borja-Tabora, LM Vargas, H Velásquez, MT Alera, V Sierra, ... The Lancet 395 (10234), 1423-1433, 2020 | 215 | 2020 |
| Three years efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003) L Rivera, S Biswal, X Sáez-Llorens, H Reynales, E López-Medina, ... Clinical Infectious Diseases, 2021 | 130 | 2021 |
| Within-host viral dynamics of dengue serotype 1 infection HE Clapham, V Tricou, N Van Vinh Chau, CP Simmons, NM Ferguson Journal of the Royal Society Interface 11 (96), 20140094, 2014 | 113 | 2014 |
| Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial V Tricou, X Sáez-Llorens, D Yu, L Rivera, J Jimeno, AC Villarreal, E Dato, ... The Lancet 395 (10234), 1434-1443, 2020 | 101 | 2020 |
| Etiology and epidemiology of diarrhea in hospitalized children from low income country: a matched case-control study in Central African Republic S Breurec, N Vanel, P Bata, L Chartier, A Farra, L Favennec, T Franck, ... PLoS neglected tropical diseases 10 (1), e0004283, 2016 | 101 | 2016 |
| Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised … X Sáez-Llorens, V Tricou, D Yu, L Rivera, S Tuboi, P Garbes, A Borkowski, ... The Lancet Infectious Diseases 17 (6), 615-625, 2017 | 94 | 2017 |
| Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a … X Sáez-Llorens, V Tricou, D Yu, L Rivera, J Jimeno, AC Villarreal, E Dato, ... The Lancet infectious diseases 18 (2), 162-170, 2018 | 93 | 2018 |
| Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination E López-Medina, S Biswal, X Saez-Llorens, C Borja-Tabora, L Bravo, ... The Journal of Infectious Diseases, 2020 | 70 | 2020 |
| High-resolution analysis of intrahost genetic diversity in dengue virus serotype 1 infection identifies mixed infections KTD Thai, MR Henn, MC Zody, V Tricou, NM Nguyet, P Charlebois, ... Journal of virology 86 (2), 835-843, 2012 | 66 | 2012 |
| Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised … V Tricou, JG Low, HM Oh, YS Leo, S Kalimuddin, L Wijaya, J Pang, ... Vaccine 38 (6), 1513-1519, 2020 | 36 | 2020 |
| Surveillance of canine rabies in the Central African Republic: impact on human health and molecular epidemiology V Tricou, J Bouscaillou, E Kamba Mebourou, FD Koyanongo, E Nakouné, ... PLoS Neglected Tropical Diseases 10 (2), e0004433, 2016 | 24 | 2016 |
| Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial M Turner, A Papadimitriou, P Winkle, N Segall, M Levin, M Doust, ... Human Vaccines & Immunotherapeutics 16 (10), 2456-2464, 2020 | 22 | 2020 |
| Genetic characterization of Chikungunya virus in the Central African Republic M Desdouits, B Kamgang, N Berthet, V Tricou, C Ngoagouni, A Gessain, ... Infection, Genetics and Evolution 33, 25-31, 2015 | 20 | 2015 |
| Hepatitis E virus outbreak associated with rainfall in the Central African Republic in 2008-2009 V Tricou, J Bouscaillou, GL Laghoe-Nguembe, A Béré, X Konamna, ... BMC Infectious Diseases 20, 1-7, 2020 | 16 | 2020 |
| Measles outbreak in Northern Central African Republic 3 years after the last national immunization campaign V Tricou, M Pagonendji, C Manengu, J Mutombo, RO Mabo, ... BMC Infectious Diseases 13, 1-6, 2013 | 15 | 2013 |
| Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4· 5-year results from a phase 3, randomised, double-blind, placebo-controlled trial V Tricou, D Yu, H Reynales, S Biswal, X Saez-Llorens, C Sirivichayakul, ... The Lancet Global Health 12 (2), e257-e270, 2024 | 13 | 2024 |
Cameron P. SimmonsMonash UniversityPotvrđena adresa e-pošte na worldmosquito.org
